Lin Ye, Cai Hong
Department of Gastroenterology, Ganzhou People's Hospital, 16 Meiguan Avenue, Ganzhou, Jiangxi 341000, PR China; The Affiliated Ganzhou Hospital of Nanchang University, 16 Meiguan Avenue, Ganzhou, Jiangxi 341000, PR China.
Department of Gastroenterology, Ganzhou People's Hospital, 16 Meiguan Avenue, Ganzhou, Jiangxi 341000, PR China; The Affiliated Ganzhou Hospital of Nanchang University, 16 Meiguan Avenue, Ganzhou, Jiangxi 341000, PR China.
Biomed Pharmacother. 2023 Apr;160:114362. doi: 10.1016/j.biopha.2023.114362. Epub 2023 Feb 3.
The incidence of cancer is increasing globally, and it is the most common cause of death. The identification of novel cancer diagnostic and prognostic biomarkers is important for developing cancer treatment strategies and reducing mortality. SHCSH2 domain-binding protein 1 (SHCBP1) is a protein that specifically binds to the SH2 domain of Src homology-collagen. It participates in the regulation of a variety of signal transduction pathways and can activate a variety of signaling molecules to perform a series of physiological functions. SHCBP1 is expressed in a variety of human tissues, but its abnormal expression in various systems is associated with cancer. SHCBP1 is abnormally expressed in a variety of tumors, and plays roles in almost all aspects of cancer biology (such as cell proliferation, apoptosis prevention, invasion, and metastasis) through various possible mechanisms. Its expression level is related to the clinicopathological characteristics of patients. In addition, the SHCBP1 expression pattern is closely related to cancer type, stage, and other clinical variables. Therefore, SHCBP1 is a promising tumor biomarker for cancer diagnosis and prognosis and a potential therapeutic target. This article reviews the expression, biological functions, mechanisms, and potential clinical significance of SHCBP1 in various human tumors to provide a new theoretical basis for clinical molecular diagnosis, molecular targeted therapy, and scientific research on cancer.
全球癌症发病率正在上升,且它是最常见的死亡原因。鉴定新型癌症诊断和预后生物标志物对于制定癌症治疗策略和降低死亡率至关重要。SHCSH2结构域结合蛋白1(SHCBP1)是一种特异性结合Src同源胶原蛋白SH2结构域的蛋白质。它参与多种信号转导途径的调控,并能激活多种信号分子以执行一系列生理功能。SHCBP1在多种人体组织中表达,但其在各种系统中的异常表达与癌症相关。SHCBP1在多种肿瘤中异常表达,并通过各种可能机制在癌症生物学的几乎所有方面(如细胞增殖、抗凋亡、侵袭和转移)发挥作用。其表达水平与患者的临床病理特征相关。此外,SHCBP1的表达模式与癌症类型、分期及其他临床变量密切相关。因此,SHCBP1是一种有前景的用于癌症诊断和预后的肿瘤生物标志物以及潜在的治疗靶点。本文综述了SHCBP1在各种人类肿瘤中的表达、生物学功能、机制及潜在临床意义,为癌症的临床分子诊断、分子靶向治疗及科研提供新的理论依据。